Key Takeaways
- CG Oncology (CGON) CEO Arthur Kuan bought $2.4 million of the company’s stock on Nov. 18, and Chief Commercial Officer Isabel Kalofonos bought shares the same day.
- The buys came two days after a Phase 3 trial win and one day after a downgrade. In between, the company’s first FDA filing slipped into 2027.
- Analysts expect $411 million of revenue in 2028. Johnson & Johnson’s (JNJ) Inlexzo and ImmunityBio’s (IBRX) Anktiva together already sell about $140 million a quarter in the same bladder cancer market.
- Every analyst’s price target is above the $78.88 Kuan paid, so the numbers back his buy, but the payoff depends on filings in 2027.
CG Oncology Chairman and CEO Arthur Kuan just bought $2.4 million of his company’s stock, two days after a Phase 3 trial win he called “a defining milestone for CG Oncology.”
His new chief commercial officer, Isabel Kalofonos, made her first purchase the same day.
She’ll need that confidence: CG’s drug, cretostimogene, is headed for a bladder cancer market where Johnson & Johnson and ImmunityBio are already selling.
A big win, then a later filing
On Nov. 6, CG said it expected to finish its first FDA filing this quarter. That filing covers patients whose cancer no longer responds to the standard BCG treatment.
Then on Nov. 16, its PIVOT-006 trial cut the risk of the cancer coming back by 68% in intermediate-risk and high-grade Ta patients, and the stock hit $85, climbing towards the 52-week high of $93.95.
But the same release said CG would broaden that first filing “based on FDA feedback,” which pushes it into 2027.
On Nov. 17, RBC Capital analyst Leonid Timashev downgraded the stock to Sector Perform from Outperform, even though he raised his target to $97 from $80.
He argued that the “major value inflection” is now behind CG. The stock fell that day. At $80, it’s 15% below its high, though it’s still up 88% over the past year.
TIKR tracks 14 analysts on CG Oncology. How many say “Buy”?
See the full breakdown of Buy, Hold, and Sell ratings on CG Oncology, along with Wall Street’s revenue and earnings estimates, all in one place. More than 500,000 investors use TIKR to research stocks like this one. See CG Oncology’s Analyst Ratings.
Kuan added 15% to his stake
Kuan’s Form 4, filed Nov. 18, shows he bought 30,000 shares that day at an average price of $78.88. That brings his stake to 228,916 shares, 15% more than he held before and worth about $18.3 million at today’s price.
Kalofonos joined in October. Her own Form 4 shows she bought 3,751 shares through a trust at an average price of $79.75.
My read: a CEO who adds 15% the day after a downgrade doesn’t think the later filing changes much. It’s the kind of buy worth flagging when you track what insiders are buying.
Do the numbers back him at $78.88?
Analysts see almost no revenue until a launch, then a steep climb:

Consensus has $65.9 million for 2027 and $411 million for 2028. But RBC doesn’t expect a launch before 2028, so that 2027 figure looks generous to me.
The 2028 figure looks easier to reach. J&J said on its Q3 call that Inlexzo sold “north of $90 million” in the quarter. ImmunityBio’s Anktiva brought in $48.7 million, up 53% from a year earlier.
That’s about $140 million a quarter from a market CG hasn’t entered yet, though CG will arrive third at best.
The consensus target has climbed with the data:

It’s $110 now, up from $71 a year ago and 38% above today’s price.
Among the 14 analysts covering CG, the lowest target is $87, still 10% above what Kuan paid. Morgan Stanley raised its own target to $117 on Nov. 18.
A bet on 2028
So the numbers back Kuan at $78.88: every target is above his price, and CG has cleared its biggest hurdle with PIVOT-006. The risk is the wait.
CG had $984.5 million in cash and securities on Sept. 30, which it says will fund operations through 2029. But launches are expensive, and a stock sale after this run wouldn’t surprise me.
One CEO’s buy shows confidence, and the case still depends on the filings.
The next tests are the full PIVOT-006 data at the Society of Urologic Oncology meeting on Dec. 2, and a first filing that has to go in early enough in 2027 to keep 2028’s $411 million within reach.
So what is CG Oncology stock actually worth?
TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what CG Oncology could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!